The Digital Biomarker Company

About The Digital Biomarker Company

The Digital Biomarker Company (TDBC) is a cutting-edge Health Tech firm committed to transforming global healthcare through advanced disease detection and monitoring as well as digital biomarker analysis. Based on its groundbreaking “non-invasive Fiber Optic Physiological Monitoring Technology” (nFOPT) featuring unparalleled sensitivity, ease of use and patient comfort, TDBC is poised to revolutionize how healthcare providers detect and monitor diseases, particularly in areas such as elderly care, diabetes management, sleep apnea and SIDS prevention. Regarding sleep apnea, the 100% unobtrusive and cost-efficient, patented and award-winning fiberoptic technology (nFOPT) is unique in that it provides real-time sleep apnea information on par with PSG, accurately identifying OSA, CSA, MSA and offering big opportunities for improvements in the diagnosis, treatment and monitoring of sleep apnea. To date, nFOPT has over 300 implementations in clinics and care centers with over 100,000 patients monitored over more than 10 years. Algorithms, developed based on big data and Al, prove that the system is capable of making highly accurate correlations that can offer breakthroughs in diagnosis, early detection, personalized medicine and also in the pharmaceutical development process well beyond sleep medicine. TDBC is headquartered in Singapore, leveraging the region’s robust ecosystem for AI, machine learning, and big data analytics in healthcare.

View contact profiles from The Digital Biomarker Company